Eberlein TJ - Search Results

1

Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.

Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ. Schoof DD, et al. Among authors: eberlein tj. Cancer Res. 1988 Sep 1;48(17):5007-10. Cancer Res. 1988. PMID: 3261630

2

The systemic complement activation caused by interleukin-2/lymphokine-activated killer-cell therapy of cancer causes minimal systemic neutrophil activation.

Moore FD Jr, Schoof DD, Rodrick M, Eberlein TJ. Moore FD Jr, et al. Among authors: eberlein tj. Int J Cancer. 1991 Oct 21;49(4):504-8. doi: 10.1002/ijc.2910490405. Int J Cancer. 1991. PMID: 1917149

3

The role of interleukin-2 in cancer immunotherapy.

Eberlein TJ, Schoof DD. Eberlein TJ, et al. Compr Ther. 1991 Jan;17(1):49-56. Compr Ther. 1991. PMID: 2001612

4

Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex.

Schoof DD, Selleck CM, Massaro AF, Jung SE, Eberlein TJ. Schoof DD, et al. Among authors: eberlein tj. Cancer Res. 1990 Feb 15;50(4):1138-43. Cancer Res. 1990. PMID: 2137027

5

Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.

Massaro AF, Schoof DD, Rubinstein A, Zuber M, Leonard-Vidal FJ, Eberlein TJ. Massaro AF, et al. Among authors: eberlein tj. Cancer Res. 1990 May 1;50(9):2587-92. Cancer Res. 1990. PMID: 2139356

6

Human tumor-infiltrating lymphocyte (TIL) cytotoxicity facilitated by anti-T-cell receptor antibody.

Schoof DD, Jung SE, Eberlein TJ. Schoof DD, et al. Among authors: eberlein tj. Int J Cancer. 1989 Aug 15;44(2):219-24. doi: 10.1002/ijc.2910440205. Int J Cancer. 1989. PMID: 2503456

7

Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.

Eberlein TJ, Rodrick ML, Massaro AF, Jung SE, Mannick JA, Schoof DD. Eberlein TJ, et al. Cancer Immunol Immunother. 1989;30(3):145-50. doi: 10.1007/BF01669422. Cancer Immunol Immunother. 1989. PMID: 2598183 Free PMC article.

8

Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells.

Silberstein DS, Schoof DD, Rodrick ML, Tai PC, Spry CJ, David JR, Eberlein TJ. Silberstein DS, et al. Among authors: eberlein tj. J Immunol. 1989 Mar 15;142(6):2162-7. J Immunol. 1989. PMID: 2784151

9

Ibuprofen causes reduced toxic effects of interleukin 2 administration in patients with metastatic cancer.

Eberlein TJ, Schoof DD, Michie HR, Massaro AF, Burger U, Wilmore DW, Wilson RE. Eberlein TJ, et al. Arch Surg. 1989 May;124(5):542-7. doi: 10.1001/archsurg.1989.01410050032005. Arch Surg. 1989. PMID: 2785376

10

A new regimen of interleukin 2 and lymphokine-activated killer cells. Efficacy without significant toxicity.

Eberlein TJ, Schoof DD, Jung SE, Davidson D, Gramolini B, McGrath K, Massaro A, Wilson RE. Eberlein TJ, et al. Arch Intern Med. 1988 Dec;148(12):2571-6. Arch Intern Med. 1988. PMID: 3264142

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

171 results

Search Page

Filters